VivoSeq
Oncology

Biphasic Mesothelioma

6

Pipeline Programs↗

2

Active Trials↗

5

Companies Involved↗

Biphasic Mesothelioma is an early-stage landscape with 6 programs across 5 companies. The most active players are Roche, Bristol-Myers Squibb, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

0/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 2M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 3G

Gynecologic Oncology Group

1 program

Phase 3A

Avyxa

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

6programs
Small molecule350%
Monoclonal antibody350%

Modality classified for 100% of 6 pipeline programs.

Analysis

Trial Status

3

clinical trials

Terminated1 · 33%
Active, not recruiting1 · 33%
Recruiting1 · 33%

Clinical Trials

Trial Activity

Phase III Randomized Trial of Pleurectomy/Decortication Plus Systemic Therapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM)
Terminated·NRG Oncology·Phase 3·NCT04158141·16 enrolled
A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma
Active, not recruiting·National Cancer Institute (NCI)·Phase 1·NCT03228537·28 enrolled
Official Title Neoadjuvant Immunotherapy in Sarcomatoid Mesothelioma
Recruiting·Alliance for Clinical Trials in Oncology·Phase 2·NCT05647265·26 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)